Genmab Reports EPCORE DLBCL-1 Trial Results, Significant PFS Improvement Observed
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Clinical Trial Results: Genmab's EPCORE DLBCL-1 trial demonstrated a significant improvement in progression-free survival (PFS) with epcoritamab monotherapy, showing a hazard ratio of 0.74, indicating potential clinical advantages for patients with relapsed or refractory DLBCL.
- Patient Recruitment: The global study enrolled 483 patients, with 73% having received two or more prior therapies and ineligible for high-dose chemotherapy and autologous stem cell transplant, highlighting the potential application of epcoritamab in complex cases.
- Safety Analysis: Adverse events observed were consistent with the known safety profile of epcoritamab, and further analysis will explore the impact of the COVID-19 pandemic and the increasing availability of novel anti-lymphoma therapies to ensure patient safety and efficacy.
- Future Development Plans: Genmab and AbbVie will engage with global regulatory authorities to discuss next steps, with data anticipated in 2026 from two additional Phase 3 trials evaluating epcoritamab across different treatment lines.
Analyst Views on GMAB
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 41.00 USD with a low forecast of 32.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
1 Hold
1 Sell
Moderate Buy
Current: 33.850
Low
32.00
Averages
41.00
High
48.00
Current: 33.850
Low
32.00
Averages
41.00
High
48.00
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
